Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$4.26 -9.6%	$1.82	$0.55 ▼ $6.19	$337.01M	3.06	1.25 million shs	262,552 shs
PRTA Prothena	$6.52 +3.7%	$6.33	$4.32 ▼ $25.42	$338.57M	0.01	801,106 shs	1.02 million shs
VOR Vor Biopharma	$2.40 -10.1%	$0.49	$0.13 ▼ $3.27	$299.90M	2.04	4.55 million shs	30.76 million shs
ZNTL Zentalis Pharmaceuticals	$1.27 +6.7%	$1.32	$1.01 ▼ $5.44	$85.62M	1.59	1.45 million shs	2.05 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	-11.47%	+8.28%	+348.53%	+588.60%	+470,999,900.00%
PRTA Prothena	-2.78%	+3.62%	+16.27%	-39.98%	-68.95%
VOR Vor Biopharma	+41.64%	+64.81%	+1,093.03%	+385.45%	+194.05%
ZNTL Zentalis Pharmaceuticals	-4.80%	+2.59%	-21.71%	+14.42%	-67.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	0.3981 of 5 stars	1.0	0.0	3.0	1.7	0.0
PRTA Prothena	3.0546 of 5 stars	4.2	2.0	1.0	1.7	1.3
VOR Vor Biopharma	3.9437 of 5 stars	4.3	5.0	2.8	1.7	0.6
ZNTL Zentalis Pharmaceuticals	1.5551 of 5 stars	3.3	2.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	-29.58% Downside
PRTA Prothena	2.33	Hold	$31.50	383.13% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	134.52% Upside
ZNTL Zentalis Pharmaceuticals	2.50	Moderate Buy	$8.37	558.79% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, PRTA, CTOR, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00
5/27/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A
PRTA Prothena	$135.16M	2.60	N/A	N/A	$9.05 per share	0.72
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	1.36	N/A	N/A	$4.73 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-53.88%	-18.86%	N/A
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$3.13	0.00	N/A	N/A	N/A	-65.48%	-51.05%	8/8/2025 (Estimated)

Latest ZNTL, PRTA, CTOR, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q2 2025	CTOR Citius Oncology	-$0.09	-$0.11	-$0.02	-$0.11	$5.74 million	N/A
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.11	0.36	0.05
PRTA Prothena	N/A	9.00	9.00
VOR Vor Biopharma	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
PRTA Prothena	97.08%
VOR Vor Biopharma	97.29%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
PRTA Prothena	9.20%
VOR Vor Biopharma	2.90%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	71.55 million	68.28 million	N/A
PRTA Prothena	130	53.83 million	48.88 million	Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	70.59 million	Optionable

ZNTL, PRTA, CTOR, and VOR Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

June 26, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

June 20, 2025 | investing.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE

June 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.comC

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%

April 10, 2025 | aaii.comA

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%

April 2, 2025 | aaii.comA

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | globenewswire.com

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

March 27, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

March 26, 2025 | globenewswire.com

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025 | globenewswire.com

Zentalis presents updated clinical data on azenosertib as SGO 2025

March 16, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

March 15, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop
Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks
By Gabriel Osorio-Mazilli | June 9, 2025
View Why Goldman Sachs Suddenly Boosted These 3 Trucking Stocks
Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
By Thomas Hughes | June 30, 2025
View Top 5 Stocks for July: Momentum-Driven Picks to Watch Now
Why Unity Software May Be the AI Breakout No One Saw Coming
By Gabriel Osorio-Mazilli | June 9, 2025
View Why Unity Software May Be the AI Breakout No One Saw Coming

ZNTL, PRTA, CTOR, and VOR Company Descriptions

Citius Oncology NASDAQ:CTOR

$4.26 -0.45 (-9.55%)

Closing price 04:00 PM Eastern

Extended Trading

$4.36 +0.10 (+2.32%)

As of 07:54 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Prothena NASDAQ:PRTA

$6.52 +0.23 (+3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$6.43 -0.09 (-1.32%)

As of 06:37 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Vor Biopharma NYSE:VOR

$2.40 -0.27 (-10.11%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 +0.14 (+5.83%)

As of 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.27 +0.08 (+6.72%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 0.00 (0.00%)

As of 07:56 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time